Using cancer data of the Familial Gastrointestinal Cancer Registry in Toronto, Lynch syndrome patients with MSH2 mutations are at an increased risk of developing not only upper tract urothelial cancer but also bladder cancer, and could be offered appropriate screening (26). This evidence concerns the gene MSH2 and cancer.